Superworth

Aethlon Medical price to sales ratio AEMD

Market value divided by revenue over the last twelve months, since 2012.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
7.4×
Nov 2023
8-year median
38.5×
8-year range
6.3× to 192×
Peer median
1.4×

Aethlon Medical's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Nov 2023, at 7.4×.

On the days it had one over the last 8 years, its median was 38.5×, from 6.3× in Oct 2023 to 192× in Aug 2022.

Price to sales ratio over time

The dashed line is the 8-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
20237.4×6.3×18.8×
2022191×23.7×192×
202131.0×23.5×129×
202048.1×15.1×56.9×
201912.1×11.1×92.9×
2018n/m a value too high to mean anything
2017n/m a value too high to mean anything
2016n/m a value too high to mean anything
201570.4×34.5×114×
201464.0×19.9×115×
201322.6×6.0×29.9×
20125.4×5.0×6.0×

Against its peers

Companies in Healthcare nearest Aethlon Medical's size, closest first, today.

CompanyPrice to sales ratio
AEMDAethlon Medicaln/m
OXBROXBRIDGE RE HOLDINGS2.8×
EDUCEducational Development0.4×
GTIMGood Times Restaurants0.1×
MDRRMedalist Diversified1.6×
BCGBinah Capital0.1×
VIPVulcan Infrastructure & Power0.4×
MXCMexco Energy3.0×
CKXCKX Lands31.0×
MSGMMotorsport Games1.5×
ATCHAtlasClear1.2×
Peer median1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Aethlon Medical

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.